BioRestorative Therapies Aktie

BioRestorative Therapies für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A3C9XF / ISIN: US0906556065

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
16.07.2025 15:13:31

EQS-News: From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain

EQS-News: Benzinga / Key word(s): Healthcare
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain

16.07.2025 / 15:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


By Meg Flippin Benzinga

DETROIT, MICHIGAN - July 16, 2025 (NEWMEDIAWIRE) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga’s All-Access. 

68779642da846f54e516130c_1

BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to achieve those goals. The company’s flagship product candidate, BRTX-100, just completed a phase 2 clinical trial for chronic lumbar disc disease (cLDD), which Alstodt was on hand to discuss with Benzinga.

“Data from the first 36 patients was highly encouraging," Alstodt told Benzinga in the interview. “At 52 weeks over 74% of participants demonstrated greater than 50% improvement in function and over 72% reported a greater than 50% reduction in pain, both substantially exceeding the FDA’s clinically meaningful threshold of 30%,” Alstodt said the phase 2 outcome set the stage for a pivotal trial or even accelerated path to approval. 

BRTX-100 is an autologous stem cell product for chronic lower back pain. It uses a patient’s stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. During the interview, Alstodt told Benzinga that he thinks what makes BRTX-100 different is that instead of masking the pain, like opioids and injectables, the BioRestorative product candidate is targeting the root cause. The goal of the phase 2 trials is to enroll a total of 99 patients, which the CEO said is tracking well. An announcement on that front is expected soon. 

But that’s not all Alstodt revealed in this wide-ranging interview. From BioRestorative’s expansion plans to what’s next for the company, the executive had a lot to share in this must-watch All Access interview. 

Watch the full interview here: 

https://www.youtube.com/watch?v=7NrNkBtUT4s

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.


News Source: Benzinga


16.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Benzinga
United States
ISIN: US0906556065
EQS News ID: 2170720

 
End of News EQS News Service

2170720  16.07.2025 CET/CEST

Analysen zu BioRestorative Therapies Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel